ArticleDiscover oncology2025
A retrospective and comparative analysis of survival in testicular non-germ cell tumors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTesticular cancer is the most frequently diagnosed malignancy in men aged 15–35, predominantly comprising Testicular germ cell tumors (TGCTs). However, less than 5% are classified as testicular non-germ cell tumors (TNGCTs), which are often overlooked despite their aggressive nature and poorer outcomes. The present study aimed to assess the prognosis of TNGCTs and assess the risks of death due to TNGCTs vs. non-cancer causes to provide an in-depth understanding of TNGCTs.
methodsWe used The Surveillance, Epidemiology, and End Results (SEER) database as our source of data for analysis. Overall survival (OS) and cancer-specific survival were assessed using the Kaplan–Meier method.
resultsA total of 1826 patients were identified. Our results suggested that TNGCTs had a significantly worse OS compared to TGCTs, with a hazard ratio of 7.85(95% CI 7.26–8.50). The five-year survival rate for patients with TNGCTs was approximately 50%, particularly for hematolymphoid tumors compared to the other tumor category in TNGCTs, with a HR of 1.79(95% CI 1.55–2.06). Hazards of TNGCTs-related death peaked at the beginning and diminished onward. Additionally, the risk of dying from other causes surpassed cancer-specific deaths approximately 4.5 years after diagnosis.
conclusionsTNGCTs bring great challenges in prognosis and management, emphasizing the need for awareness, appropriate follow-up strategies, and the development of effective treatment, especially for hematolymphoid tumors with the worst prognosis in TNGCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.